Lenvatinib and Pembrolizumab Before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer
Status:
Recruiting
Trial end date:
2024-08-05
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well lenvatinib and pembrolizumab before surgery work in
treating patients with kidney cancer that has spread from its original site of growth to
nearby tissues or lymph nodes but has not spread to other places in the body
(non-metastatic). Lenvatinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving lenvatinib and pembrolizumab before
surgery may kill more tumor cells.